This therapeutic concept targets the calcineurin-NFAT (Nuclear Factor of Activated T-cells) signaling pathway to restore calcium homeostasis and reduce neuroinflammation in Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. The approach aims to normalize activity-dependent transcriptional programs while dampening pathological calcium-driven inflammation. [1]
Calcium (Ca²⁺) signaling is fundamentally disrupted in neurodegenerative diseases: [2]
Alzheimer's disease:
Parkinson's disease:
ALS:
Calcineurin is a calcium/calmodulin-dependent serine/threonine phosphatase: [3]
Pathological Role: [4]
Therapeutic Approach: [5]
Existing drugs with calcineurin inhibitor activity:
Challenge: Systemic immunosuppression at therapeutic doses
Solution:
Selective inhibitors:
Allosteric modulators:
NFAT isoform-selective approaches:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7 | Established pathway (calcineurin); novel application to neurodegeneration; selective inhibitors in development |
| Mechanistic Rationale | 8 | Strong evidence of calcineurin overactivation in AD/PD models; clear link to neuroinflammation |
| Root-Cause Coverage | 6 | Addresses calcium dysregulation upstream of many pathological processes |
| Delivery Feasibility | 6 | Existing drugs repurposed; local delivery methods established |
| Safety Plausibility | 6 | Immunosuppression risk manageable with local delivery; well-characterized safety profile |
| Combinability | 8 | Synergistic with anti-inflammatory, antioxidant, and mitochondrial therapies |
| Biomarker Availability | 7 | NFAT phosphorylation status; calcineurin activity in lymphocytes; cytokine levels |
| De-risking Path | 7 | Preclinical models established; biomarkers available; path to clinic clear |
| Multi-disease Potential | 8 | AD, PD, ALS, MS, stroke - all involve calcium dysregulation |
| Patient Impact | 7 | Addresses inflammation and plasticity - meaningful for patients |
Total: 70/100
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7/10/10 | Calcineurin-NFAT pathway is established; CNS-selective targeting is novel |
| Mechanistic Rationale | 7/10/10 | Calcineurin regulates immune gene transcription; modulation affects neuroinflammation |
| Addresses Root Cause | 7/10/10 | Addresses T-cell mediated neuroinflammation; unique mechanism |
| Delivery Feasibility | 6/10/10 | Brain-penetrant immunosuppressants available; selectivity challenging |
| Safety Plausibility | 5/10/10 | Calcineurin inhibitors have significant systemic toxicity |
| Combinability | 6/10/10 | Limited combination due to immunosuppression |
| Biomarker Availability | 6/10/10 | NFAT translocation measurable; inflammatory markers available |
| De-risking Path | 7/10/10 | Well-established drug class; CNS-selectivity is key challenge |
| Multi-disease Potential | 6/10/10 | Primarily considered for neuroinflammation in transplantation |
| Patient Impact | 6/10/10 | Could suppress pathological neuroinflammation if CNS-selectivity achieved |
| Total | 63/100 |
| Phase | Duration | Key Milestones |
|---|---|---|
| Lead Optimization | 6-12 months | Screen candidates, optimize PK/PD |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in patients |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Brain penetration failure | Medium | High | Early PK/PD screening |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center design |
Bhatia et al. Calcineurin in Alzheimer's disease (2022). 2022. ↩︎
Norris et al. Calcineurin and neuroinflammation (2021). 2021. ↩︎
Rehman et al. NFAT in Parkinson's disease (2023). 2023. ↩︎
Crestani et al. Calcineurin inhibitors in neurodegeneration (2021). 2021. ↩︎